This week, the laboratory was again at the centre of the biggest stories: a first Ebola vaccine trial opened in the middle of an outbreak with no approved vaccine for its strain, two major FDA approvals depended on laboratory tests to select the right patients, and Pakistan's own polio laboratory network showed how surveillance testing guides a sub-national campaign starting next week. For technologists and students, the lesson is practical — a test result is never just a number; it decides who gets a new treatment, who needs follow-up, and where a health system should act next.

1First Ebola vaccine trial begins in DR Congo as cases pass 9,700

On October 23, 2026, the first participants were vaccinated in Bunia in the Tumaini trial, testing whether the existing Ervebo vaccine — approved for the Zaire strain — offers any cross-protection against the Bundibugyo strain behind the DR Congo outbreak, for which no vaccine or treatment is approved. The outbreak has passed 9,700 cases with more than 4,600 deaths.

Source: Malay Mail (AFP), October 24, 2026 · Read full story

2FDA approves first hepatitis B treatment aimed at functional cure

On October 20, 2026, the FDA approved GSK's Hibsago (bepirovirsen) for adults without cirrhosis on antiviral therapy with suppressed virus and hepatitis B surface antigen at or below 3,000 IU/mL. In two phase 3 trials, 19% achieved functional cure versus none on placebo.

Source: Pharmaceutical Executive, October 20, 2026 · Read full story

3FDA expands prostate cancer drug approval to earlier disease, guided by genetic testing

On October 26, 2026, the FDA approved talazoparib (Talzenna) with enzalutamide for metastatic prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test. In the TALAPRO-3 trial of 599 patients, the combination cut the risk of radiographic progression or death by about half.

Source: U.S. FDA, October 26, 2026 · Read full story

4WHO Western Pacific countries agree to speed up hypertension, tobacco, immunization and AI plans

At its October 19–22, 2026 meeting in Manila, WHO's Western Pacific Regional Committee — covering 2.2 billion people — endorsed action plans on hypertension control, tobacco control and immunization, and guidance for responsible AI use in health. Hypertension affects one in three adults in the region.

Source: WHO, October 22, 2026 · Read full story

5New endometrial cancer drug extends survival by almost seven months in phase 3 trial

Results from the TroFuse-005 trial, presented at ESMO 2026 and published in The Lancet on October 26, 2026, showed sacituzumab tirumotecan extended median overall survival to 19.0 months versus 12.1 months with chemotherapy. The drug reduced the risk of death by 32% and the risk of progression or death by 41%.

Source: Merck / Business Wire, October 26, 2026 · Read full story

Pakistan and Asian Development Bank discuss healthcare reform, local vaccine production and drug regulation

Federal Health Minister Syed Mustafa Kamal met an Asian Development Bank delegation on October 21, 2026, to discuss technical assistance for local vaccine manufacturing, Drug Regulatory Authority of Pakistan reforms, the National Institute of Health, 13 vaccines and a Universal Medical Record. Separately, parents were urged to ensure every child under five receives two drops of polio vaccine in the sub-national campaign, running November 2 to 8, 2026, in 97 selected districts.

Source: Pakistan Today, October 21, 2026 · Read full story

WHO polio laboratory in Islamabad tests about 67,800 samples a year to track poliovirus

Donors and partners visited the WHO Regional Reference Laboratory for Polio at Pakistan's National Institute of Health on October 23, 2026, ahead of World Polio Day. The laboratory tests approximately 65,400 stool samples and 2,400 environmental samples annually, forming one of the world's largest polio surveillance networks.

Source: UrduPoint (APP), October 23, 2026 · Read full story

Sindh's mobile healthcare services reach over 5 million patients, with 1.27 million laboratory tests

Officials told a review meeting in Karachi on October 22, 2026, that Sindh's mobile diagnostic and emergency services treated more than 5.01 million patients between June 2016 and September 2026, conducting 1,274,322 laboratory and other medical tests. Twenty mobile units — 13 diagnostic and seven health units — now serve 17 districts.

Source: Vitals News, October 22, 2026 · Read full story

FDA clears rapid 20-minute vaginitis PCR panel with CLIA waiver

On October 22, 2026, the FDA granted dual 510(k) clearance and a CLIA waiver to bioMérieux's BIOFIRE SPOTFIRE Vaginitis Panel, giving eight results — covering bacterial vaginosis, Candida species and Trichomonas — from one swab in about 20 minutes at the point of care.

Source: Clinical Lab Products, October 22, 2026 · Read full story

FDA clears AI software estimating coronary blood flow from CT scans

Elucid's FFR-IQ software received FDA 510(k) clearance on October 21, 2026, for non-invasive estimation of fractional flow reserve from coronary CT angiography. The company cites the ELUCIDATE FFR-CT study with 92.2% sensitivity and 93.1% specificity.

Source: Cardiac Interventions Today, October 21, 2026 · Read full story

New York approves APOE genotyping test on dried blood spots, plasma and urine

New York State Department of Health approval, dated October 23 and reported October 26, 2026, expanded the APOE Genotyping test to include dried blood spots, plasma and urine. The test identifies variants linked to Alzheimer's disease risk; it does not diagnose Alzheimer's disease.

Source: The Manila Times / GlobeNewswire, October 26, 2026 · Read full story

FDA grants accelerated approval to ravulizumab for IgA nephropathy

Ravulizumab received accelerated approval, announced October 21 and reported October 22, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk of progression — the first C5 complement inhibitor approved for this use. Kidney-function benefit is not yet shown; week-106 data must confirm it.

Source: Pharmacy Times, October 22, 2026 · Read full story

Heart-drug combination during septic-shock surgery cuts kidney injury — JAMA randomised trial

In a randomised trial of 584 adults across 39 hospitals in China, published October 26, 2026, adding dobutamine to norepinephrine during septic-shock surgery reduced new or worsening acute kidney injury within a week. Rapid heart rate was more common with the combination, with no increase in serious cardiac complications.

Source: MedicalXpress reporting the JAMA paper, October 26, 2026 · Read full story

Trastuzumab rezetecan more than doubles progression-free survival in ERBB2-low advanced breast cancer — JAMA phase 3 trial

Published online October 23, 2026, the HORIZON-Breast06 trial (551 patients, 73 hospitals in China) found median progression-free survival of 16.4 months versus 6.8 months with physician's-choice chemotherapy. Overall survival data were immature, and the trial was China-only, limiting generalisability.

Source: JAMA, October 23, 2026 · Read full story

Seven more mpox patients hospitalised in Karachi as Sindh tightens infection control

Seven more mpox patients, including an infant, were hospitalised in Karachi over the past week, Dawn reported on October 24, 2026, bringing Sindh's total this year to 98 cases with 11 deaths. Authorities strengthened surveillance and contact tracing and directed health facilities to strictly follow infection-control measures.

Source: Dawn, October 24, 2026 · Read full story

Ebola outbreak grows more complex as Nigeria confirms its first case

The WHO warned on October 22, 2026, that the Bundibugyo Ebola outbreak had become more complex, with Nigeria confirming its first case on October 20 and Kenya reporting its first cases earlier in October. Health officials were tracing contacts and investigating possible links between the Nigerian and Kenyan patients.

Source: Al Jazeera, October 22, 2026 · Read full story

NIH week-40 surveillance: suspected malaria still high in Sindh, and most tested fevers are not malaria

Pakistan reported 80,137 suspected malaria cases in epidemiological week 40, per the NIH bulletin posted on October 24, 2026, with Sindh accounting for 69,294; Karachi's seven districts together reported 1,206. These are suspected, not confirmed, cases: Sindh laboratories confirmed only 448 of 7,825 tested samples (5.7%). The practical message is test before treatment for fever.

Source: Pakera summary of the NIH bulletin, week 40, October 24, 2026 · Read full story